home / stock / navb / navb news

NAVB News and Press, Navidea Biopharmaceuticals Inc. From 08/01/22

Stock Information
Company Name: Navidea Biopharmaceuticals Inc.
Stock Symbol: NAVB
Market: NYSE
Website: navidea.com
Menu
NAVB NAVB Quote NAVB Short NAVB News NAVB Articles NAVB Message Board
Get NAVB Alerts

News, Short Squeeze, Breakout and More Instantly...
NAVB - Navidea Biopharmaceuticals Reminds Investors of Today's Deadline to be a Shareholder of Record for the Previously Announced Rights Offering

To be a shareholder of record, investors are advised to own Navidea Biopharmaceuticals stock by 4:00 PM ET, Monday, August 1, 2022 to account for T+2 settlement timing Record date established as Wednesday, August 3, 2022 Navidea Biopharmaceuticals, Inc. (NYSE America...
NAVB - Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “Increased Mac...

NAVB - Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today provided an informational update to stockholders regarding its propose...

NAVB - Navidea biopharmaceuticals secures additional bridge loan funding of 1M

Navidea Biopharmaceuticals ( NYSE: NAVB ) largest shareholder and Board Vice Chair John K. Scott, funded an additional $1M under the secured bridge loan that was executed on April 10, 2022 . “We are delighted to have the continued funding in place from Mr. ...
NAVB - Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on July 1, 2022, its largest shareholder and Vice Chair...

NAVB - Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract titled, “TAM Targeted Imag...

NAVB - Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced acceptance of its abstract titled, “CD206 Targeted De...
NAVB - Navidea Biopharmaceuticals, Inc. (NAVB) Management on Q1 2022 Results - Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NAVB) Q1 2022 Results Conference Call May 12, 2022 5:00 PM ET Company Participants Michael Rosol - CMO Erika Eves - VP, Finance & Administration Conference Call Participants Michael Okunewitch - Maxim Group Presentation Operator Welcome to the Navidea Bio...

NAVB - Navidea Biopharm GAAP EPS of -$0.10

Navidea Biopharm press release (NYSE:NAVB): Q1 GAAP EPS of -$0.10. $1.2 million in cash and cash equivalents. For further details see: Navidea Biopharm GAAP EPS of -$0.10

NAVB - Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results

Conference Call to be held Thursday, May 12, 2022 at 5:00 pm (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutic...
Previous 10 Next 10